The effectiveness of the Russian Sputnik V vaccine against the coronavirus looks very promising, and modifying the medication if the virus mutates should not be complicated, Nobel laureate in physiology and medicine, Australian virologist Peter Charles Doherty said.
"It’s [Sputnik V vaccine] 90% [rate of being] effective look[s] great, and Russia has a long history of developing good vaccines. The two adenovirus vector strategy makes sense. <...> The same basic technology used in the Janssen and AstraZeneca vaccines. Of course, if the virus changes significantly by mutation - it looks as though it may be in the process of doing it - they’ll [the creators of the vaccine] have to ‘tweak it’ a bit, but that’s straightforward," TASS cited him as saying.
Earlier, The Lancet medical journal published the results of the Phase Three clinical trials of the Russian vaccine highlighting that it is one of the safest and the most effective worldwide. The drug’s efficacy amounts to 91.6%, while among vaccinated volunteers over 60 years of age that rate came to 91.8%. Antibodies to the coronavirus after being immunized with the Sputnik V jab were detected in 98% of the inoculated volunteers.
